Search research articles
Contact Us
Filters
Showing results (161-170 of 247) with videos related to
Page
of 25
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2011
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors
Francesco Atzori, Josep Tabernero, Andrés Cervantes, et al.
NPJ Precision Oncology
|
April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
Omar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2023
Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes
Ryan A Denu, Richard K Yang, Alexander J Lazar, et al.
Clinical and Translational Science
|
May 23, 2026
Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity
Marije B Overdijk, Kristin Strumane, Ruth Plummer, et al.
Cancer Chemotherapy and Pharmacology
|
June 9, 2018
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
Jordi Rodon, Alejandro Pérez-Fidalgo, Ian E Krop, et al.
Cell Reports. Medicine
|
March 2, 2022
Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
Edwards Pradenas, Benjamin Trinité, Víctor Urrea, et al.
The Oncologist
|
February 8, 2024
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers
Natalie Y L Ngoi, Tin-Yun Tang, Catia F Gaspar, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 21, 2025
ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer
Joaquim Bosch-Barrera, Purificación Estévez-García, Paloma Martín-Martorell, et al.
Cancer
|
October 18, 2021
Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified
Luana G Sousa, Kaiwen Wang, Danice Torman, et al.
Med (New York, N.Y.)
|
June 28, 2025
Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers
Steven H Lin, Vivek Subbiah, Evan N Cohen, et al.
Page
of 25
Search research articles
Search
Showing results (161-170 of 247) with videos related to
Sort By:
Page
of 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2011
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors
Francesco Atzori, Josep Tabernero, Andrés Cervantes, et al.
NPJ Precision Oncology
|
April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
Omar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2023
Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes
Ryan A Denu, Richard K Yang, Alexander J Lazar, et al.
Clinical and Translational Science
|
May 23, 2026
Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity
Marije B Overdijk, Kristin Strumane, Ruth Plummer, et al.
Cancer Chemotherapy and Pharmacology
|
June 9, 2018
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
Jordi Rodon, Alejandro Pérez-Fidalgo, Ian E Krop, et al.
Cell Reports. Medicine
|
March 2, 2022
Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
Edwards Pradenas, Benjamin Trinité, Víctor Urrea, et al.
The Oncologist
|
February 8, 2024
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers
Natalie Y L Ngoi, Tin-Yun Tang, Catia F Gaspar, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 21, 2025
ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer
Joaquim Bosch-Barrera, Purificación Estévez-García, Paloma Martín-Martorell, et al.
Cancer
|
October 18, 2021
Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified
Luana G Sousa, Kaiwen Wang, Danice Torman, et al.
Med (New York, N.Y.)
|
June 28, 2025
Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers
Steven H Lin, Vivek Subbiah, Evan N Cohen, et al.
Page
of 25